The future of health is hidden in your microbiome, and we at ENBIOSIS guide you to discover what is concealed within your gut. By harnessing microbiome organisms to develop scientific innovations, products, and services, we aim to enhance human health.

The number of microorganisms we host is 1.3 times higher than the number of our own cells. The trillions of microorganisms that our body hosts are referred to as the microbiota, and these microorganisms, along with their genomes, genome products, and environmental effects, collectively make up the microbiome.

The microbiome, which resides within us, communicates with us through the metabolites they produce, even though we may not be aware of it. A highly diverse and balanced microbiome protects us against various diseases, particularly chronic-complex diseases, digestive system-related conditions, and mental health issues. It also contributes to an improved quality of life by aiding in the healing process.

ENBIOSIS Biotechnology combines artificial intelligence and microbiome science to offer personalized health solutions. Trillions of gut bacteria in our extensive database are analyzed with the assistance of advanced artificial intelligence models. Our areas of expertise encompass gut microbiome analysis, personalized nutrition and dietary technologies, a personalized supplement suggestion engine, next-generation probiotics and biotherapeutics, and microbiome-based diagnostics.

Enbiosis provides the world's first clinically proven AI-powered gut health solution and collaborates with healthcare professionals and partners in the healthcare industry to reach more patients. This solution includes a comprehensive gut health report alongside personalized food and supplement recommendations. Additionally, Enbiosis offers specialized tools for healthcare professionals to enhance patient compliance with diet plans through personalized recipes and automatically generated diet plans, fostering better engagement between practitioners and patients.

Founded in 2019 by a serial entrepreneur, a bioinformatics engineer with over 15 years of experience in the field of microbiome, and a microbiologist, Enbiosis introduced its market entry product—an AI-driven microbiome analysis-based personalized nutrition plan in 2020. Through clinical trials, Enbiosis has demonstrated the effectiveness of its technology in patients with gut health issues, especially those suffering from irritable bowel syndrome (IBS) and chronic constipation. The creation of personalized supplement formulas and the launch of the personalized supplement suggestion engine followed the introduction of the market entry product, and Enbiosis subsequently launched its SaaS platform to rapidly expand globally.

Enbiosis has received numerous accolades, including the UK Government's TechRocketship 2022 winner among 256 tech scale-up companies, Sanofi Country Winner, completion of the Bayer Accelerator program, victory in the NN Insurance global competition, finalist in the NutraIngredients Europe & Asia Awards, and recognition as the Probiota Americas Scientific Frontiers Winner.